BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

Rhea-AI Summary

BioRestorative Therapies (NASDAQ: BRTX) announced an upcoming interview with CEO Lance Alstodt on Famela and Friends Talk Radio, focusing on the company's clinical development pipeline. BioRestorative is currently conducting a Phase 2 trial for its lead therapy candidate, BRTX-100, aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 U.S. centers, assessing safety and efficacy. The company also highlighted its Metabolic Program utilizing stem cells from brown adipose tissue.

Positive

• Conducting a Phase 2 trial for BRTX-100, indicating progression towards market entry.
• Trial involves 99 patients, suggesting substantial research investment.

Negative

• Phase 2 trial results not yet available, which may pose uncertainty.

MELVILLE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that its CEO, Lance Alstodt, will be interviewed on Famela and Friends Talk Radio Show to discuss the Company’s progress and updates on its clinical development pipeline.

BioRestorative is currently executing a Phase 2 trial to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of its lead cell therapy candidate, BRTX-100. A total of up to 99 eligible patients will be randomized at 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.

The radio show, which airs Sundays 7-8 pm on AM1170/FM96.1, is hosted by Famela Ramos along with "friends" Kalina O'Connor and Wais Kaihani.

“We are excited to have the opportunity to be guests of Famela and Friends”, said Lance Alstodt, the Company’s CEO. “We look forward discussing the clinical advancements of the company’s lead cell therapy candidate to treat chronic lumbar disc disease as well as our Metabolic Program using cells derived from brown adipose fat tissue.”

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC^™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

• Metabolic Program (ThermoStem^®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Email: ir@biorestorative.com

FAQ

What is the focus of BioRestorative Therapies' Phase 2 trial for BRTX-100?

The Phase 2 trial focuses on evaluating the safety and preliminary efficacy of BRTX-100 for chronic lumbar disc disease.

When is the CEO of BioRestorative Therapies appearing on a radio show?

CEO Lance Alstodt will appear on Famela and Friends Talk Radio on October 20, 2022.

How many patients are involved in the BRTX-100 trial?

Up to 99 eligible patients are participating in the Phase 2 trial.

What is the primary goal of the BRTX-100 therapy?

BRTX-100 aims to provide a non-surgical treatment for painful lumbosacral disc disorders.

What other programs does BioRestorative Therapies have besides BRTX-100?

In addition to BRTX-100, BioRestorative is developing a Metabolic Program targeting obesity with stem cells derived from brown adipose tissue.

Where is the BRTX-100 trial being conducted?

The trial is being conducted at 15 centers across the United States.